US-based pharmaceutical company DifGen Pharmaceuticals LLC announced on Tuesday the successful completion of the European Decentralised Procedure (DCP) for Tafamidis 61 mg Capsules, marking the company's first major regulatory milestone in Europe.

Building on this regulatory milestone, DifGen intends to engage with established pharmaceutical companies across Europe to evaluate potential licensing, regulatory and strategic collaboration opportunities.

DifGen is investing in complex generics, specialty pharmaceutical products and differentiated dosage forms, supported by its manufacturing and research and development infrastructure in Florida.